Tuesday 22 January 2013

Celgene's Abraxane increases survival in pancreatic cancer

(Reuters) - Celgene Corp said its Abraxane drug helped patients with advanced pancreatic cancer live an average of two months longer than chemotherapy and significantly increased the percentage of those who survived with the disease for up to two years, according to a late-stage study.

via Reuters: Health News Read More Here..

No comments:

Post a Comment